Cherington Charles's Form 4 filing
Comera Life Sciences Holdings, Inc.CMRA · filed Jan 6, 2023
- Accession no.
- 0000899243-23-001182
- Filed
- Jan 6, 2023, 4:45 PM ET
- Trade date
- Jan 4, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $914.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cherington CharlesCIK 0001448698 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2023 | Common Stock | PPurchaseAcquired | +743,243 | $1.23F1 | +$914,188.89 | 2,879,666 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 4, 2023 | Common Stock | PPurchaseAcquired | +1,486,486 | $0.25F1 | +$185,810.75 | 743,243 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On January 4, 2023, pursuant to a private placement offering by the Issuer, the Reporting Person acquired 743,243 Units, each Unit consisting of (i) one share of the Issuer's Common Stock and (ii) one Warrant to purchase two shares of Common Stock. The combined purchase price in the Offering was $1.48 per Unit, inclusive of $1.23 per share of Common Stock and $0.25 per Warrant.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.